Eye and vision (London, England) · 2026
Variation in corneal biomechanical properties following continuous cross-linking treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao ChenHao, Yao XinYu, Zhao YeWei, Wu HongJiang, Zong JiaHui, Tong XuanYa, Oehring Daniela, Yang Lan, Zhou XiaoFei, Li Ying, Shen YanJie, Ye YuFeng, Chen ShiHao, Qu Jia, Wang QinMei, Elsheikh Ahmed, Bao FangJun
Аннотация
BACKGROUND: This retrospective study aimed to evaluate the efficacy of transepithelial accelerated corneal cross-linking (transEpi ACXL) when applied separately or combined with phototherapeutic keratectomy (transPTK ACXL) in keratoconic eyes using biomechanical parameters.
METHODS: The study included eyes with progressive keratoconus treated with either continuous transEpi ACXL or transPTK ACXL with 6 months follow-up. The following parameters were assessed preoperatively and 6 months postoperatively: biomechanically corrected intraocular pressure (bIOP), maximum and mean keratometry (Kmax and Km), minimum and central corneal thickness (MCT and CCT), corneal coma, best-corrected visual acuity (BCVA), deformation amplitude ratio at 2 mm nasal/temporal (DAR2), integrated inverse radius (IIR), stiffness parameter at first applanation (SP-A1), highest concavity time (HCT) and two versions of stress-strain index (SSIv1 and SSIv2).
RESULTS: A total of 75 eyes from 72 patients were included (31 in the transEpi ACXL group and 44 in the transPTK ACXL group). The two groups were comparable in age (23.0 ± 5.0 vs. 21.3 ± 5.2 years) and TKC grade distribution (grades 1-4), with no statistically significant between-group differences (P = 0.321 and 0.766, respectively). Both groups exhibited significant reductions in IIR, and increases in SSIv1 and SSIv2 (all P < 0.05). The improvements in Kmax, coma, and SSIv2 were greater in the transPTK ACXL group than in the transEpi ACXL group (all P < 0.05). The relative difference in SSIv2 (SSIv2Rdif) exceeded those of other biomechanical parameters in both groups (transEpi ACXL: SSIv2Rdif > DAR2Rdif, IIRdif; transPTK ACXL: SSIv2Rdif > DAR2Rdif, IIRRdif, SP-A1Rdif, HCTRdif, and SSIv1Rdif, all P < 0.05).
CONCLUSIONS: TransPTK ACXL resulted in better biomechanical and visual benefits in comparison with transEpi ACXL 6 months after treatment. SSIv2 demonstrated superior performance in assessing the efficacy of corneal cross-linking.
METHODS: The study included eyes with progressive keratoconus treated with either continuous transEpi ACXL or transPTK ACXL with 6 months follow-up. The following parameters were assessed preoperatively and 6 months postoperatively: biomechanically corrected intraocular pressure (bIOP), maximum and mean keratometry (Kmax and Km), minimum and central corneal thickness (MCT and CCT), corneal coma, best-corrected visual acuity (BCVA), deformation amplitude ratio at 2 mm nasal/temporal (DAR2), integrated inverse radius (IIR), stiffness parameter at first applanation (SP-A1), highest concavity time (HCT) and two versions of stress-strain index (SSIv1 and SSIv2).
RESULTS: A total of 75 eyes from 72 patients were included (31 in the transEpi ACXL group and 44 in the transPTK ACXL group). The two groups were comparable in age (23.0 ± 5.0 vs. 21.3 ± 5.2 years) and TKC grade distribution (grades 1-4), with no statistically significant between-group differences (P = 0.321 and 0.766, respectively). Both groups exhibited significant reductions in IIR, and increases in SSIv1 and SSIv2 (all P < 0.05). The improvements in Kmax, coma, and SSIv2 were greater in the transPTK ACXL group than in the transEpi ACXL group (all P < 0.05). The relative difference in SSIv2 (SSIv2Rdif) exceeded those of other biomechanical parameters in both groups (transEpi ACXL: SSIv2Rdif > DAR2Rdif, IIRdif; transPTK ACXL: SSIv2Rdif > DAR2Rdif, IIRRdif, SP-A1Rdif, HCTRdif, and SSIv1Rdif, all P < 0.05).
CONCLUSIONS: TransPTK ACXL resulted in better biomechanical and visual benefits in comparison with transEpi ACXL 6 months after treatment. SSIv2 demonstrated superior performance in assessing the efficacy of corneal cross-linking.